Schizophrenia and Autism Spectrum Disorder (ASD) research hub

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

This study looks at new medicines (KarXT and KarX-EC) for young people aged 5-17. It checks how safe they are and if they cause any side effects for teenagers with schizophrenia or children/teenagers with autism who have a lot of irritability.